- Home
- ONEG vs OTLK Comparison
ONEG vs OTLK Comparison
Compare ONEG & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONEG
- OTLK
- Stock Information
- Founded
- ONEG 2021
- OTLK 2010
- Country
- ONEG Hong Kong
- OTLK United States
- Employees
- ONEG N/A
- OTLK N/A
- Industry
- ONEG Homebuilding
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ONEG Consumer Discretionary
- OTLK Health Care
- Exchange
- ONEG Nasdaq
- OTLK Nasdaq
- Market Cap
- ONEG 43.3M
- OTLK 48.3M
- IPO Year
- ONEG 2024
- OTLK 2016
- Fundamental
- Price
- ONEG $7.20
- OTLK $2.03
- Analyst Decision
- ONEG
- OTLK Strong Buy
- Analyst Count
- ONEG 0
- OTLK 5
- Target Price
- ONEG N/A
- OTLK $9.60
- AVG Volume (30 Days)
- ONEG 582.9K
- OTLK 871.2K
- Earning Date
- ONEG 01-01-0001
- OTLK 08-13-2025
- Dividend Yield
- ONEG N/A
- OTLK N/A
- EPS Growth
- ONEG N/A
- OTLK N/A
- EPS
- ONEG 0.12
- OTLK 0.83
- Revenue
- ONEG $60,903,000.00
- OTLK N/A
- Revenue This Year
- ONEG N/A
- OTLK N/A
- Revenue Next Year
- ONEG N/A
- OTLK $419.06
- P/E Ratio
- ONEG $52.88
- OTLK $2.50
- Revenue Growth
- ONEG 16.46
- OTLK N/A
- 52 Week Low
- ONEG $1.48
- OTLK $0.87
- 52 Week High
- ONEG $10.80
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- ONEG N/A
- OTLK 66.41
- Support Level
- ONEG N/A
- OTLK $1.56
- Resistance Level
- ONEG N/A
- OTLK $2.00
- Average True Range (ATR)
- ONEG 0.00
- OTLK 0.13
- MACD
- ONEG 0.00
- OTLK 0.03
- Stochastic Oscillator
- ONEG 0.00
- OTLK 95.88
About ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. It is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.